TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

Amir Goldkorn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.